Transfusion and Apheresis Science
Volume 41, Issue 3 , Pages 217-225 , December 2009

Clinical trials for pathogen reduction in transfusion medicine: A review

  • John McClaskey

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, United States
    • Department of Laboratory Medicine, Yale-New Haven Hospital, New Haven, CT, United States
    • ,
  • Mina Xu

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, United States
    • Department of Laboratory Medicine, Yale-New Haven Hospital, New Haven, CT, United States
    • ,
  • Edward L. Snyder

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, United States
    • Department of Laboratory Medicine, Yale-New Haven Hospital, New Haven, CT, United States
    • ,
  • Christopher A. Tormey

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, United States
    • Department of Laboratory Medicine, Yale-New Haven Hospital, New Haven, CT, United States
    • Pathology and Laboratory Medicine Service, VA Connecticut Healthcare System, West Haven, CT, United States
    • Corresponding Author InformationCorresponding author. Address: Department of Laboratory Medicine, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208035, New Haven, CT 06520, United States. Tel.: +1 203 932 5711x2964; fax: +1 203 937 4746.

References 

  1. Epstein JS, Vostal JG. FDA approach to evaluation of pathogen reduction technology. Transfusion. 2003;43:1347–1350
  2. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev. 2009;23:124–133
  3. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol. 2006;19:205–242
  4. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci. 2006;35:83–90
  5. Octapharma. octaplas® Australian Approved Product Information Sheet (PI). <http://www.octapharma.com/Australia/au_octaplas.php> [accessed 29.06.09].
  6. Schmidt I, Blumel J, Seitz H, Willkommen H, Lower J. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang. 2001;81:228–235
  7. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang. 1998;74(Suppl. 1):203–206
  8. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion. 2000;40:1203–1206
  9. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma – a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang. 1998;74(Suppl. 1):207–212
  10. Doyle S, O’Brien P, Murphy K, Fleming C, O’Donnell J. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrin. 2003;14:283–287
  11. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med. 2004;14:39–44
  12. Zeiler T, Wittmann G, Zimmermann R, Hintz G, Huhn D, Riess H. The effect of virus inactivation on coagulation factors in therapeutic plasma. Br J Haematol. 2000;111:986–987
  13. Solheim BG, Hellstern P. Composition, efficacy, and safety of S/D-treated plasma. Transfusion. 2003;43:1176–1178
  14. Sandler SG. It is time to bring back solvent–detergent plasma. Curr Opin Hematol. 2007;14:640–641
  15. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423–435
  16. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44:1496–1504
  17. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion. 2005;45:580–590
  18. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol. 2001;20:533–550
  19. Ciaravino V, McCullough T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang. 2003;85:171–182
  20. Tice RR, Gatehouse D, Kirkland D, Speit G. The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. Mutat Res. 2007;630:50–68
  21. Schlenke P, Hervig T, Isola H, et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion. 2008;48:697–705
  22. de Valensart N, Rapaille A, Goossenaerts E, Sondag-Thull D, Deneys V. Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA. Vox Sang. 2009;96:213–218
  23. Moog R, Frohlich A, Mayaudon V, Lin L. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apher. 2004;19:185–191
  24. Lin L, Conlan MG, Tessman J, Cimino G, Porter S. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion. 2005;45:1610–1620
  25. OhUigin C, McConnell DJ, Kelly JM, van der Putten WJ. Methylene blue photosensitised strand cleavage of DNA: effects of dye binding and oxygen. Nucleic Acids Res. 1987;15:7411–7427
  26. Wainwright M. Methylene blue derivatives – suitable photoantimicrobials for blood product disinfection?. Int J Antimicrob Agents. 2000;16:381–394
  27. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med. 2001;11:31–36
  28. Mohr H, Knuver-Hopf J, Gravemann U, Redecker-Klein A, Muller TH. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion. 2004;44:886–890
  29. Seghatchian J, Walker WH, Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci. 2008;38:271–280
  30. Simonsen AC, Sorensen H. Clinical tolerance of methylene blue virus-inactivated plasma. A randomized crossover trial in 12 healthy human volunteers. Vox Sang. 1999;77:210–217
  31. Wainwright M, Phoenix DA, Gaskell M, Marshall B. Photobactericidal activity of methylene blue derivatives against vancomycin-resistant Enterococcus spp.. J Antimicrob Chemother. 1999;44:823–825
  32. Girones N, Bueno JL, Carrion J, Fresno M, Castro E. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang. 2006;91:285–291
  33. Osselaer J-C, Debry C, Goffaux M, et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion. 2008;48:108–117
  34. Garwood M, Cardigan RA, Drummond O, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion. 2003;43:1238–1247
  35. Lorenz M, Muller M, Jablonka B, Vigh T, Kirchmaier CM. High doses of methylene blue/light treatment crosslink the A-alpha-subunit of fibrinogen: influence of this photooxidization on fibrinogen binding to platelets. Haemostasis. 1998;28:17–24
  36. Mallinckrodt Baker Inc. Material safety data sheet: methylene blue. <http://www.jtbaker.com/msds/englishhtml/m4381.htm>. [accessed 29.06.09].
  37. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15–21
  38. Joshi PC. Comparison of the DNA-damaging property of photosensitised riboflavin via singlet oxygen (1O2) and superoxide radical mechanisms. Toxicol Lett. 1985;26:211–217
  39. Davies RJ, Joshi PC, Kumar S, Stevenson C. Oligonucleotide-sequencing studies of guanine photodamage sensitized by acetone and riboflavin. Biochem Soc Trans. 1990;18:327
  40. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang. 2004;87:82–90
  41. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44:877–885
  42. Goodrich RP, Gilmour D, Hovenga N, Keil SD. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009 [Epub ahead of print].
  43. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008;22:133–153
  44. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B(2)) for pathogen-reduction. Vox Sang. 2009;97:26–33
  45. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45:911–919
  46. Piquet Y, Janvier G, Selosse P, et al. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang. 1992;63:251–256
  47. Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang. 1992;63:178–185
  48. Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang. 2000;79:161–167
  49. Santagostino E, Mancuso ME, Morfini M, et al. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica. 2006;91:634–639
  50. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227–1234
  51. Chekrizova V, Murphy WG. Solvent–detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med. 2006;16:85–91
  52. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang. 2002;82:9–14
  53. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion. 2005;45:1362–1372
  54. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 2002;42:1302–1307
  55. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006;46:1693–1704
  56. Politis C, Kavallierou L, Hantziara S, et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years’ experience. Vox Sang. 2007;92:319–326
  57. Alvarez-Larran A, Del Rio J, Ramirez C, et al. Methylene blue-photoinactivated plasma vs. Fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang. 2004;86:246–251
  58. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101:2426–2433
  59. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004;104:1534–1541
  60. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion. 2005;45:1864–1875
  61. Murphy S, Snyder E, Cable R, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion. 2006;46:24–33
  62. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion. 2004;44:1732–1740
  63. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion. 2006;46:731–740
  64. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion. 2008;48:1061–1071
  65. Ciaravino V, Hanover J, Lin L, Sullivan T, Corash L. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion. 2009;49:985–994
  66. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45:1335–1341
  67. Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang. 2006;90:279–285
  68. Seghatchian J, de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci. 2006;35:189–196
  69. Trannoy LL, van Hensbergen Y, Lagerberg JW, Brand A. Photodynamic treatment with mono-phenyl-tri-(N-methyl-4-pyridyl)-porphyrin for pathogen inactivation in cord blood stem cell products. Transfusion. 2008;48:2629–2637

PII: S1473-0502(09)00147-5

doi: 10.1016/j.transci.2009.09.008

Transfusion and Apheresis Science
Volume 41, Issue 3 , Pages 217-225 , December 2009

Article Tools